Clinical Trials Logo

Relapsed or Refractory Lymphomas clinical trials

View clinical trials related to Relapsed or Refractory Lymphomas.

Filter by:
  • None
  • Page 1

NCT ID: NCT06132503 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

Start date: January 3, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory (R/R) lymphomas and solid tumors. The secondary objectives are to characterize the pharmacokinetics (PK) of LP-284 and to assess clinical activity of LP-284.

NCT ID: NCT04458389 Recruiting - Clinical trials for Relapsed or Refractory Lymphomas

A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas

Start date: December 7, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A multicenter, open-label, dose-escalation and dose-expansion phase 1/2 study, to evaluate TY101 safety, tolerability, pharmacokinetic characteristics, effectiveness and immunogenicity in patients with Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas. The study includes two parts: dose escalation and expansion cohort to evaluate the tolerability and efficacy.